SAN DIEGO, May 23, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of David A. Ramsay as Chief Financial Officer.

Halozyme Therapeutics, Inc (NASDAQ:HALO): In Friday's trading session, Halozyme Therapeutics, Inc (NASDAQ:HALO) up by 5.51%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) closed up to $7.98 after gaining 18.40% during the day and hitting its day's high of $8.06 and a low of $7.25.

Canadian Solar Inc. (NASDAQ:CSIQ) closed down by 1.49% at $7.26 in the Wednesday's trading session. The share price of Canadian hit a high of $7.98 and a low of $7.23 during the day, after opening at $7.75.

Analysts are expecting Halozyme Therapeutics to come in with a loss of 15 cents per share, more than year-earlier reported loss of 14 cents per share.

... Inc. (NASDAQ:INFI) and DryShips, Inc. (NASDAQ:DRYS). Halozyme Therapeutics, Inc. (NASDAQ:HALO) a biopharmaceutical company that concentrates on the development of human enzymes finished yesterday at (+18.40%) on 5,329,593 shares traded.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares jumped 12.31% to $7.57. The company, on May 15, announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, ...

Huntington Beach, CA -- (SBWIRE) -- 05/16/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) a biopharmaceutical company that engages in the research, development, and commercialization of human enzymes is currently up (+18.25%) on 2,717,587 shares traded after Halozyme Announced To Present ...

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care.